BioHealth News
AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet…
Read More
Novavax is Powering the Future of Vaccines Through R&D and Value-creating Business Strategy
January 13, 2025 - By Ruxandra Draghia-Akli, MD, PhD, Executive Vice President, Head of R&D and Elaine O’Hara, Executive Vice President, Chief Strategy Officer As…
Read More
VEDP: Booming Virginia clusters provide a supply chain blueprint for increasing drug accessibility, affordability
Like his fellow Type 1 diabetics, Alec Smith took insulin every day to regulate his blood sugar. Costs to treat his condition topped $1,000…
Read More
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
GAITHERSBURG, Md., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for…
Read More
The Baltimore Banner: University of Maryland merges engineering and medicine to turn ideas into companies
It’s Baltimore’s latest move toward becoming a tech hub Meredith Cohn - 1/11/2025 - It looks like a rolling suitcase, a mask and some tubes, but for…
Read More
ARPA-H RAPID Program: Rare Disease AI/ML for Precision Integrated Diagnostics
*NOTE: Solution Summary due: February 14, 2025The Big Question What if we could end the rare disease diagnostic odyssey? The Problem Collectively, rare diseases…
Read More
Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics
FREDERICK, Md., Jan. 9, 2025 /PRNewswire/ -- Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today…
Read More
QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a…
Read More
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies…
Read More
Montgomery County Economic Development Corporation President and CEO Bill Tompkins Plans to Step Down at the End of His Current Term
Montgomery County, MD — The Montgomery County Economic Development Corporation (MCEDC) announced that Bill Tompkins will step down as President & CEO when his…
Read More
Emmes Group Company, Essex Management Appoints David Loose as Chief Executive Officer
ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ -- Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce…
Read More
Why the DMV Region Is Thriving as a Hub for Startups and Innovation
The Washington D.C., Maryland, and Virginia (DMV) region has quickly become one of the nation’s top destinations for startups and tech innovation. With over…
Read More
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax®
GAITHERSBURG, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at…
Read More
IonQ Completes Acquisition of Qubitekk, Solidifying Leadership in Quantum Networking
COLLEGE PARK, Md.--(BUSINESS WIRE)-- IonQ (NYSE: IONQ), a leader in the quantum computing and networking industry, today announced the completion of its acquisition of substantially…
Read More
I-Mab Focuses on Advancing Givastomig as Lead Cancer Therapy in Clinical Development
ROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the…
Read More